How well do boosters work? Depends on your genes

Computer modeling links a person's genes to whether producing more antibodies will help them fight off the disease.

10:39 AM

Author | Jim Lynch

woman scientist laptop lab dark
Kelly Arnold, senior author of a paper that uses a computational model to understand how genetics may influence an individual’s immune response to vaccine boosting. Photo: Brenda Ahearn/Michigan Engineering

Genetics play an important role in how our bodies respond to vaccines and booster shots, suggesting that certain protective responses elicited by vaccination  could be more effective with personalization, according to a new study led by University of Michigan researchers.

The team also identified a particular form of an antibody-related gene that predicts, at a population level, whether boosting to produce more antibodies will be effective for increasing innate immune responses.

"What's most interesting with this work is the concept of personalized variability and understanding direct links between vaccine responses and different genes people have," said Kelly Arnold, U-M assistant professor of biomedical engineering and senior author of the paper in Frontiers in Immunology.

The study explored how people may respond differently to conventional boosting, which reexposes the immune system to the virus (or some portion of it) to increase antibody concentration.

However, in some people, the increase in antibody concentration may not matter as much because their genes encode for immune receptors that aren't as good at sticking to the antibodies—they're said to have a lower affinity. 

As a result, a person can have a respectable antibody count and still have a poor immune response. So one theoretical alternate immune-boosting route could be to design vaccines that tweak the structure of the antibodies—making those antibodies more likely to stick to a person's immune cell receptors.

"Depending on your genetic background, we've found that vaccine boosting may be more or less effective in activating certain innate immune functions," Arnold said. "And in some people, where boosting the concentrations of antibodies was ineffective, being able to change the affinity of antibodies could be the more successful route. Though this is still a theoretical concept and not yet possible in practice."

Arnold's team, working with partners in Australia, Thailand and the U.S., created a computer model to determine how different genetic factors influence innate immune responses induced by vaccine boosting. It uses data and plasma samples obtained by the University of Melbourne from the only moderately protective HIV vaccine trial to date. 

The plasma samples from trial participants—basically blood samples minus the red blood cells—showed the amount and type of antibodies produced after vaccination. 

"In a mixed population of people, we've also shown how one specific genotype would drive whether that population was responsive to changes in antibody concentrations expected from traditional boosting," Arnold said. 

Modeling showed that, in a gene that encodes for a specific type of antibody (IgG1), different variations can predict how effective boosting to increase antibody levels will be in a given population. Some populations in the HIV trial showed that increasing antibody levels resulted in no change in the innate immune functions that were being evaluated. 

"What that tells us is that in populations with certain genetic variations, traditional boosting methods to increase antibody concentrations may not be as effective at improving innate immune functions," Arnold said.

Adjuvants are the vaccine ingredients designed to improve the body's immune response.

Last year, Arnold's team utilized data from the same trial to highlight why certain vaccines influence people differently. In the future, both studies could lead to new design principles for vaccines that take an individual's personalized characteristics into account.

The research was funded by the Australia National Health & Medical Research Center, the American Foundation for AISD Research Mathilde Krim Fellowship and the University of Michigan.

The collaboration included the University of Melbourne, Monash University and the Burnet Institute in Australia; Mahidol University, the Ministry of Public Health and the Armed Forces Research Institute of Medical Science in Thailand; and the Ragon Institute of Massachusetts General Hospital, Harvard University and the Massachusetts Institute of Technology in the United States.

This article was originally published by Engineering Research News.

More Articles About: Body Work covid-19 COVID-19 Vaccine Community Health Genetics infectious disease
Health Lab word mark overlaying blue cells
Health Lab

This article is from the Health Lab digital publication.

Media Contact Public Relations

Department of Communication at Michigan Medicine



Get a weekly digest of medical research and innovation, straight to your inbox.

Featured News & Stories pediatrician talking with mother at exam questions
Health Lab
Checklist for the checkup: Some parents may not be making the most of well child visits
While many parents keep recommended well visits with their child’s primary provider, some may consider more proactive steps to make checkups as productive as possible
colorful pills falling in a line
Health Lab
For COVID-19, do supplements help?
An expert cautions about becoming too enamored with pills.
gas stove pot cooking
Health Lab
Is your gas stove really hurting you and your family?
A pulmonologist discusses the risks and offers tips for protecting your health in your home
crowded blurred people walking in city streets
Health Lab
How Americans learned science in a hurry during a pandemic
People were plunged into the issue of COVID-19
Watercolor Painting People Rain Umbrella
Health Lab
Support from others in stressful times can ease impact of genetic depression risk
Stress can interact with genetic vulnerability to depression, and with added or lacking support from friends and family, to affect depressive symptoms.
scientists together at computer in white coats
Health Lab
Researchers uncover new cell types involved in osteoarthritis
And the development of a new slow-release drug seeks to target them